Develops engineered toxin bodies for cancer therapy, focusing on targeted biologic drugs and immunotoxins.
Molecular Templates, Inc., headquartered in Austin, Texas, is a pioneering clinical-stage biopharmaceutical company dedicated to advancing biologic therapeutics for the treatment of cancer and other severe diseases. Established in 2001, Molecular Templates focuses on developing its innovative pipeline through its proprietary biologic engineered toxin body (ETB) drug platform. This platform serves as the foundation for multiple therapeutic candidates aimed at addressing critical unmet needs in oncology.
Among its leading candidates, Molecular Templates is advancing MT-5111 through Phase I clinical trials for HER2-positive cancers, MT-0169 in Phase I trials for relapsed/refractory myeloma, and MT-6402 in Phase I trials targeting PD-1/PD-L1 antibody-resistant patients. The company's robust pipeline includes ETBs targeting various other significant cancer-related molecules such as CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45, reflecting its broad therapeutic approach.
Collaborative efforts play a pivotal role in Molecular Templates' strategy, exemplified by its partnership with Bristol Myers Squibb to develop novel products incorporating ETBs directed at multiple targets. With a commitment to innovation and patient-centric solutions, Molecular Templates continues to push boundaries in biopharmaceutical development, striving to transform the treatment landscape and improve outcomes for patients worldwide.